ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial Three ...

In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment ...

Tiziana Life Sciences Ltd’s TLSA share price has surged by 12.58%, which has investors questioning if this is right time to sell.

India, soon to be the cardiovascular disease capital, faces rising heart attack rates, especially among women who experience ...

Indigenous Nigerian food plants show promise in fighting cancer by targeting cell death and inflammation, offering support ...

Breast cancer is caused by the development of malignant cells in the breast. The malignant cells originate in the lining of the milk glands or ducts of the breast (ductal epithelium). Breast ...

At close: May 9 at 4:00:00 p.m. EDT ...

eLife is a non-profit organisation inspired by research funders and led by scientists. Our mission is to help scientists accelerate discovery by operating a platform for research communication that ...